In Patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course?

Philadelphia (Ph) negative myeloproliferative neoplasms (MPNs) are disorders caused by abnormal proliferation of myeloid cells in the peripheral blood. Mutations that are responsible for the majority of these cases are those affecting Janus kinase 2 (JAK2), Calreticulin (CalR), and myeloproliferative leukemia virus oncogene (MPL). In this study, we aimed to assess the frequency of CalR and MPL gene mutations and the clinical effects of these mutations in JAK2 gene unmutated MPN patients who were followed up. Despite the lack of statistical significance in 46 patients, it was notable that CalR mutations were more common in patients with esansiyel thrombocytosis (ET), while MPL mutations were only found in patients with primary myelofibrosis (PMF). We found no correlation between thrombosis, leukemic transformation, and driver mutations. The triple negative group had a lower survival rate, but this difference was not statistically significant.